Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geodrill Announces Record First Quarter 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called... see more

Recent & Breaking News (NDAQ:GLUE)

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

GlobeNewswire October 17, 2023

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2023

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

GlobeNewswire July 26, 2023

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

GlobeNewswire May 30, 2023

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

GlobeNewswire May 23, 2023

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2023

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

GlobeNewswire April 17, 2023

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

GlobeNewswire March 23, 2023

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 16, 2023

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 3, 2023

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

GlobeNewswire January 9, 2023

Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

GlobeNewswire November 10, 2022

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

GlobeNewswire November 1, 2022

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire October 31, 2022

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

GlobeNewswire October 20, 2022

Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader

GlobeNewswire September 6, 2022

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

GlobeNewswire August 11, 2022

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

GlobeNewswire May 11, 2022

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

GlobeNewswire April 8, 2022